Cargando…
HLA-F*01:01 presents peptides with N-terminal flexibility and a preferred length of 16 residues
HLA-F belongs to the non-classical HLA-Ib molecules with a marginal polymorphic nature and tissue-restricted distribution. HLA-F is a ligand of the NK cell receptor KIR3DS1, whose activation initiates an antiviral downstream immune response and lead to delayed disease progression of HIV-1. During th...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6525141/ https://www.ncbi.nlm.nih.gov/pubmed/30941482 http://dx.doi.org/10.1007/s00251-019-01112-1 |
_version_ | 1783419663143665664 |
---|---|
author | Hò, Gia-Gia T. Heinen, Funmilola J. Huyton, Trevor Blasczyk, Rainer Bade-Döding, Christina |
author_facet | Hò, Gia-Gia T. Heinen, Funmilola J. Huyton, Trevor Blasczyk, Rainer Bade-Döding, Christina |
author_sort | Hò, Gia-Gia T. |
collection | PubMed |
description | HLA-F belongs to the non-classical HLA-Ib molecules with a marginal polymorphic nature and tissue-restricted distribution. HLA-F is a ligand of the NK cell receptor KIR3DS1, whose activation initiates an antiviral downstream immune response and lead to delayed disease progression of HIV-1. During the time course of HIV infection, the expression of HLA-F is upregulated while its interaction with KIR3DS1 is diminished. Understanding HLA-F peptide selection and presentation is essential to a comprehensive understanding of this dynamic immune response and the molecules function. In this study, we were able to recover stable pHLA-F*01:01 complexes and analyze the characteristics of peptides naturally presented by HLA-F. These HLA-F-restricted peptides exhibit a non-canonical length without a defined N-terminal anchor. The peptide characteristics lead to a unique presentation profile and influence the stability of the protein. Furthermore, we demonstrate that almost all source proteins of HLA-F-restricted peptides are described to interact with HIV proteins. Understanding the balance switch between HLA-Ia and HLA-F expression and peptide selection will support to understand the role of HLA-F in viral pathogenesis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00251-019-01112-1) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6525141 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-65251412019-06-05 HLA-F*01:01 presents peptides with N-terminal flexibility and a preferred length of 16 residues Hò, Gia-Gia T. Heinen, Funmilola J. Huyton, Trevor Blasczyk, Rainer Bade-Döding, Christina Immunogenetics Original Article HLA-F belongs to the non-classical HLA-Ib molecules with a marginal polymorphic nature and tissue-restricted distribution. HLA-F is a ligand of the NK cell receptor KIR3DS1, whose activation initiates an antiviral downstream immune response and lead to delayed disease progression of HIV-1. During the time course of HIV infection, the expression of HLA-F is upregulated while its interaction with KIR3DS1 is diminished. Understanding HLA-F peptide selection and presentation is essential to a comprehensive understanding of this dynamic immune response and the molecules function. In this study, we were able to recover stable pHLA-F*01:01 complexes and analyze the characteristics of peptides naturally presented by HLA-F. These HLA-F-restricted peptides exhibit a non-canonical length without a defined N-terminal anchor. The peptide characteristics lead to a unique presentation profile and influence the stability of the protein. Furthermore, we demonstrate that almost all source proteins of HLA-F-restricted peptides are described to interact with HIV proteins. Understanding the balance switch between HLA-Ia and HLA-F expression and peptide selection will support to understand the role of HLA-F in viral pathogenesis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00251-019-01112-1) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2019-04-02 2019 /pmc/articles/PMC6525141/ /pubmed/30941482 http://dx.doi.org/10.1007/s00251-019-01112-1 Text en © The Author(s) 2019, corrected publication 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Article Hò, Gia-Gia T. Heinen, Funmilola J. Huyton, Trevor Blasczyk, Rainer Bade-Döding, Christina HLA-F*01:01 presents peptides with N-terminal flexibility and a preferred length of 16 residues |
title | HLA-F*01:01 presents peptides with N-terminal flexibility and a preferred length of 16 residues |
title_full | HLA-F*01:01 presents peptides with N-terminal flexibility and a preferred length of 16 residues |
title_fullStr | HLA-F*01:01 presents peptides with N-terminal flexibility and a preferred length of 16 residues |
title_full_unstemmed | HLA-F*01:01 presents peptides with N-terminal flexibility and a preferred length of 16 residues |
title_short | HLA-F*01:01 presents peptides with N-terminal flexibility and a preferred length of 16 residues |
title_sort | hla-f*01:01 presents peptides with n-terminal flexibility and a preferred length of 16 residues |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6525141/ https://www.ncbi.nlm.nih.gov/pubmed/30941482 http://dx.doi.org/10.1007/s00251-019-01112-1 |
work_keys_str_mv | AT hogiagiat hlaf0101presentspeptideswithnterminalflexibilityandapreferredlengthof16residues AT heinenfunmilolaj hlaf0101presentspeptideswithnterminalflexibilityandapreferredlengthof16residues AT huytontrevor hlaf0101presentspeptideswithnterminalflexibilityandapreferredlengthof16residues AT blasczykrainer hlaf0101presentspeptideswithnterminalflexibilityandapreferredlengthof16residues AT badedodingchristina hlaf0101presentspeptideswithnterminalflexibilityandapreferredlengthof16residues |